Data on occurrence, genetic characteristics and prognostic impact of complex and monosomal karyotype (CK/MK) in children with acute myeloid leukaemia (AML) are scarce. We studied CK and MK in a large unselected cohort of childhood AML patients diagnosed and treated according to Nordic Society for Paediatric Haematology and Oncology (NOPHO)-AML protocols 1993-2015. In total, 800 patients with de novo AML were included. CK was found in 122 (15%) and MK in 41 (5%) patients. CK and MK patients were young (median age 2Á1 and 3Á3 years, respectively) and frequently had FAB M7 morphology (24% and 22%, respectively). Refractory disease was more common in MK patients (15% vs. 4%) and stem cell transplantation in first complete remission was more frequent (32% vs. 19%) compared with non-CK/non-MK patients. CK showed no association with refractory disease but was an independent predictor of an inferior event-free survival (EFS; hazard ratio [HR] 1Á43, P = 0Á03) and overall survival (OS; HR 1Á48, P = 0Á01). MK was associated with a poor EFS (HR 1Á57, P = 0Á03) but did not show an inferior OS compared to non-MK patients (HR 1Á14, P = 0Á62). In a large paediatric cohort, we characterized AML with non-recurrent abnormal karyotype and unravelled the adverse impact of CK and MK on prognosis.
Approximately 80% of paediatric acute myeloid leukaemia (AML) patients harbour chromosomal abnormalities, and cytogenetics is considered one of the most important prognostic factors in this cohort (de Rooij et al, 2015) . Although overall (OS) and event-free survival (EFS) rates have increased remarkably during the last 30 years and currently reach almost 70% for OS and 50% for EFS (Lie et al, 2005; Abrahamsson et al, 2007; Rubnitz et al, 2010; Creutzig et al, 2012) , cure rates remain low in certain cytogenetic subgroups (Lie et al, 2005; Harrison et al, 2010; von Neuhoff et al, 2010; Creutzig et al, 2012 Creutzig et al, , 2016 . Relapse remains the most frequent cause of treatment failure and the main obstacle for further improvement of prognosis in paediatric AML Karlsson et al, 2017) .
A number of recurrent cytogenetic abnormalities are recognized in AML (Arber et al, 2016) and the prognostic impact of most of these balanced rearrangements have been established even though some of them are rare in children . The predictive influence of a broad spectrum of non-recurrent aberrations has not been resolved, and thus current algorithms of risk stratification may fail to identify high-risk disease entities among a large proportion of patients.
AML with numerous aberrations, designated as complex karyotype (CK), is associated with a poor prognosis in adults (Mr ozek, 2008) . CK is predominated by aberrations of chromosomal imbalances and is frequently detected in AML arising from myelodysplasia (Miesner et al, 2010) or secondary to antecedent cytotoxic therapy (Schoch et al, 2004; Kayser et al, 2011) . Previous studies have used various definitions of CK and do not uniformly establish CK as an entity with an adverse outcome in children (Harrison et al, 2010; von Neuhoff et al, 2010) . The prognostic contribution to outcome may vary between cytogenetic subgroups in patients with multiple non-recurrent aberrations and recently, the specific event of chromosome loss yielding a monosomal karyotype (MK) has been associated with an unfavourable outcome among adults (Breems et al, 2008; Medeiros et al, 2010; Perrot et al, 2011; Haferlach et al, 2012; Kayser et al, 2012; Voutiadou et al, 2013; Weinberg et al, 2014) . MK is often associated with other unfavourable risk cytogenetics, such as inv(3), -5/del(5q), -7/del(7q), and rarely combined with FLT3-internal tandem duplication (ITD) or NPM1 mutations (Kayser et al, 2012; Weinberg et al, 2014) . The negative influence on prognosis has been identified in AML patients with MK independently of the co-occurrence of CK (Breems et al, 2008; Medeiros et al, 2010; Fang et al, 2011; Haferlach et al, 2012; Kayser et al, 2012; Weinberg et al, 2014) and may be less pronounced in younger patients (Breems et al, 2008; Kayser et al, 2012; Manola et al, 2013; Weinberg et al, 2014) . A study of MK in children with AML by Manola et al (2013) indicated an adverse prognosis with OS of 52%, but included only 15 cases with MK. Another small study (Lee et al, 2016) found no dismal outcome among 10 children with MK and concomitant CK. The spectrum of genetic abnormalities in AML is highly age-dependent (Creutzig et al, 2016) and the adverse prognosis of CK and MK evident in adults may not mirror paediatric AML populations. To our knowledge, a recent study by Rasche et al (2017) is the only other study which has investigated CK and MK in a large cohort of paediatric AML (642 children with 22 cases of MK). They showed that MK was a strong and independent predictor of a dismal outcome. However, this study included both patients with core-binding factor (CBF) AML and normal karyotype in the comparison group, which may distort the interpretation of the influence of MK among children with AML.
The aim of the present study was to elucidate the occurrence, genetic characteristics and prognostic impact of CK and MK at diagnosis in a large paediatric cohort of de novo AML.
Methods

Patients
The Nordic Society for Paediatric Haematology and Oncology (NOPHO) is a collaboration between the Nordic countries (Sweden, Denmark, Norway, Finland and Iceland) . All children with AML in the Nordic countries are diagnosed, treated and subsequently followed in accordance with the same protocol. Hong Kong, Estonia and Latvia joined the Patients with myeloid leukaemia of Down syndrome, acute promyelocytic leukaemia, juvenile myelomonocytic leukaemia, AML secondary to bone marrow failure syndromes or therapy-related AML were excluded.
Cytogenetics and classification
Classic metaphase karyotyping was performed according to standard protocols and registered in the NOPHO AML database. The karyotypes were described and reviewed according to the International System for Human Cytogenetic Nomenclature (ISCN) 2013 (Shaffer et al, 2013) . Results from interphase fluorescence in situ hybridization (FISH) and molecular diagnostic tests were also included. Chromosomal gains or structural aberrations detected in at least two metaphases and chromosomal losses detected in three metaphases were considered as clonal. Constitutional karyotypes were not considered as aberrant. Karyotypes have been centrally reviewed by the NOPHO cytogenetic working groups since 1995 for Sweden and since 2000 for the rest of the Nordic countries.
MK was defined as two or more distinct autosomal chromosome monosomies or one single autosomal monosomy in association with at least one structural chromosomal aberration and in the absence of CBF translocations (Breems et al, 2008; Kayser et al, 2012; St€ olzel et al, 2016) . In tri-and tetraploid karyotypes MK was defined after loss of two or more autosomal chromosomes or a single relative monosomy with at least one structural aberration in the absence of CBF translocations considered relative to the pure ploidy. Subclonality was not an exclusion criterion.
CK was defined as at least three unrelated cytogenetic aberrations in the absence of recurrent genetic abnormalities of AML, as defined by the WHO (Arber et al, 2016) . Recurrent genetic abnormalities include t(8;21)(q22;q22), inv(16) (p13q22)/t(16;16)(p13;q22), t(9;11)(p21;q23), t(6;9)(p22; q34), inv(3)(q21q26)/t(3;3)(q21;q26) and t(1;22)(p13;q13). In tri-and tetraploid karyotypes the pure ploidy change was considered as a single abnormality. If there was an additional loss or gain of a chromosome it was considered as a single additional abnormality.
In addition, we defined a category of revised MK (MK-R), which included all MK with the exception of those with t (9;11), t(6;9), inv(3)/t(3;3) and t(1;22).
Statistics
To test the significance of differences between groups, the chisquare (v 2 ) test was applied when appropriate. The Mann-Whitney U test was used for testing continuous variables. EFS and OS were estimated using the Kaplan-Meier method, and the log rank test was used for the comparison of survival distribution. Events were defined as induction failure, induction death, death in complete remission, refractory disease, relapse or secondary malignancy. OS was defined as time from diagnosis to death from any cause or to last follow-up. In calculations of cumulative incidence of relapse (CIR), death was considered a competing event and Gray's test was applied for comparison of cumulative incidence functions. In compliance with previous studies (Breems et al, 2008; Haferlach et al, 2012; Kayser et al, 2012) , patients presenting either normal karyotype or CBF aberrations, including inv(16)/t(16;16) and t(8;21), were not included in the survival analysis, as the favourable prognostic influence of the latter independent from additional chromosomal abnormalities [e.g. sex chromosome loss (Klein et al, 2015) or del7q (Hasle, 2014) ] will skew the differences in survival, and thus overestimate the adverse influence of MK on prognosis.Refractory disease was defined as no remission (blasts ≥5%) after two induction courses. Relapse was defined as ≥5% blasts in blood or bone marrow blasts or development of extramedullary disease.
For multivariate analysis, the Cox proportional-hazard regression model was applied including the parameters of sex, age, white blood cell (WBC) count, MK and KMT2A-rearrangements other than t(9;11) as covariates. P-values were two-sided, and values less than 0Á05 were considered statistically significant. Stata/IC Version 13 (StataCorp, College Station, TX, USA) was used to perform the statistical analysis.
Results
Clinical characteristics
In total, 853 paediatric AML patients met our inclusion criteria, 53 (6%) of which were excluded owing to missing or uninformative cytogenetic data. More karyotypes were considered non-informative than previously reported (Sandahl et al, 2014) due to higher standards for accuracy. Figure 1 shows the distribution of patients according to karyotype and indicates that MK and CK overlap extensively. Of the 800 eligible patients, 41 patients (5%) had MK and 122 (15%) patients had a karyotype defined as complex. Eight patients (1%) had solely MK (MK/non-CK) and 89 (11%) patients showed CK in the absence of MK (CK/non-MK). The majority, of patients with MK (n = 33, 80%) also had complex karyotype (CK/MK). In total, 670 (84%) showed neither MK nor CK (non-CK/non-MK). Clinical characteristics for patients with MK, CK/non-MK and non-CK/non-MK are presented in Table I . Patients with CBF AML and normal karyotype were included in Table I , but excluded from the survival analysis.
Cytogenetic abnormalities were detected in 620 patients (78%). The most common recurrent aberrations involved 11q23 (n = 187, 23% of the total cohort) followed by t(8;21) (n = 98, 12%). KMT2A rearrangements other than t(9;11) were frequently part of CK (29% vs. 11%, P < 0Á001) or part of MK (27% vs. 11%, P = 0Á002).
FLT3-ITD and NPM1 mutations were uncommon among both MK and CK. Only one case (2%) with FLT3-ITD was found in the MK group vs. 64 (10%) in the non-CK/non-MK group.
Patients with CK/non-MK were significantly younger than patients without either CK or MK (median age 2Á1 vs. 7Á5, P < 0Á001). In particular the CK/non-MK group included more young children age 0-1 year in compared with non-CK/non-MK (46% vs. 22%, P < 0Á001) and less patients aged 
Years since diagnosis Event-free survival 10-18 years (15% vs. 39%, P < 0Á001). Age distribution among patients with MK did not differ significantly either from CK/non-MK patients (median age 3Á3 vs. 2Á1) or non-CK/non-MK patients (median age 3Á3 vs. 7Á5). No significant difference was found in sex distribution between the groups. However, the MK group had a female preponderance and the non-CK/non-MK group a male preponderance (male/female ratio: 0Á63 vs. 1Á2, P = 0Á054).
Among both CK/non-MK and MK patients, the FrenchAmerican-British (FAB) type M7 dominated compared with non-CK/non-MK patients, constituting 24% and 22% vs. 4%, P < 0Á001, while FAB M2 was underrepresented with 8% among CK/non-MK and 5% among MK compared with 26% among non-CK/non-MK (P < 0Á001 and P = 0Á003, respectively). Additionally, more FAB M0 patients were seen among MK patients than among the non-CK/non-MK patients (12% vs. 4%, P = 0Á014) and no MK patients showed M1 morphology (0% vs. 13%, P = 0Á013). FAB M4 was underrepresented in the CK/non-MK group compared with the non-CK/non-MK group (9% vs. 21%, P = 0Á007).
The distribution of FAB subtypes in the CK/non-MK group compared with the MK group was quite similar except for M1, which was only observed with CK/non-MK (10% vs. 0%, P = 0Á035).
MK was associated with refractory disease compared with non-CK/non-MK patients (15% vs. 4%, P = 0Á001) and CK/ non-MK patients (15% vs. 3%, P = 0Á019). For all groups, relapse was the most frequent event (Table I) .
MK patients more often received stem cell transplantation (SCT) in first complete remission (CR1) compared with other patients. MK vs. non-CK/non-MK (32% vs. 19%, P = 0Á046); MK vs CK/non-MK (32% vs. 15%, P = 0Á024) ( Table I ). For detailed information regarding karyotypes see Tables SI, SII and SIII.
Survival analysis
Median time of follow-up for patients alive was 7 years (range: 0-22).
The 5-year EFS was significantly inferior in CK (41%; 95% confidence interval [CI] 32-50%) compared with non-CK patients (50%; CI 44-56%, P = 0Á04). Patients with CK showed a lower 5-year OS compared with non-CK (59%; CI 50-68% vs. 69%; CI 64-74%, P = 0Á02, Fig 2B) . The CIR at 5 years was 45%; CI 36-55% for patients with CK and 41%; CI 36-47% in non-CK patients, P = 0Á21. Among CK patients with five or more aberrations (n = 56) the 5-year OS was higher compared with CK patients with three or four aberrations (n = 66) (65%; CI 50-76% vs. 55%; CI 42-66%, P = 0Á047). No difference in 5-year EFS was observed between the groups (≥5 aberrations: 42%; CI 29-55% vs. 3-4 aberrations: 40%; CI 28-52%, P = 0Á60) (data not shown).
In a multivariate analysis with sex, age, WBC, MK and KMT2A rearrangements other than t(9;11) included as covariates, CK was a predictor of inferior EFS (HR 1Á43; CI 1Á0-1Á97; P = 0Á03) and OS (HR 1Á71; CI 1Á2-2Á5, P = 0Á01). The adjusted HR in risk of relapse was 1Á41 (CI 0Á98-2Á01; P = 0Á07). Estimates of crude and adjusted HR are presented in Table IIA .
Outcome in the three groups (non-CK/non-MK; CK/non-MK; MK) was dichotomously compared and EFS and OS are presented in Fig 3. Due to the small number (n = 8), survival in patients with MK/non-CK was not evaluated separately. Four out of 8 patients experienced an event (2 with resistant disease, 2 with relapse) and six patients were alive at the end of follow-up.
Patients with CK/non-MK had a significantly lower 5-year OS compared with non-CK/non-MK (58%; CI 47-68% vs. OS, overall survival. *P < 0Á05. †Adjusted for sex, age and KMT2A rearrangements other than t (9;11), white blood cell count and MK.
‡Adjusted for sex, age and KMT2A rearrangements other than t (9;11) and white blood cell count.
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ª 2018 British Society for Haematology and John Wiley & Sons Ltd 69%; CI 64-74%, P = 0Á03), but no difference in OS was shown for MK compared with non-CK/non-MK (64%; CI 47-77% vs. 69%; CI 64-74%, P = 0Á31) or MK compared with CK/non-MK (64%; CI 47-77% vs. 58%; CI 47-68%, P = 0Á59). Patients with MK had a lower 5-year EFS compared with patients with non-CK/non-MK (34%; CI 20-49% vs. 50%; CI 44-56%, P = 0Á01) (Fig 3A) . No significant difference was shown when CK/non-MK was compared to the non-CK/non-MK group (44%; CI 33-55% vs. 50%; CI 44-56%, P = 0Á22) or to the MK group (44%; CI 33-55% vs. 34%; CI 20-49%, P = 0Á24).
After exclusion of patients with CBF leukaemia and normal karyotype, refractory disease remained more frequent among patients with MK (P = 0Á001). Patients with MK had a lower 5-year EFS compared to patients without MK (34%; CI 20-49% vs. 49%; CI 44-54%, P = 0Á03). The 5-year OS among patients with MK was similar to patients without MK (64%; CI 47-77% vs. 67%; CI 62-71%, P = 0Á52). The CIR at 5 years was 46%; CI 30-62% for patients with MK and 42%; CI 37-47% in non-MK patients, P = 0Á49. The survival results are presented in Fig 4. The adjusted HR in EFS for MK compared with non-MK patients was 1Á57 (CI 1Á04-1Á37, P = 0Á03) and in OS 1Á14 (CI 0Á68-1Á93, P = 0Á62). The adjusted HR in risk of relapse was 1Á16 (CI 0Á71-1Á90, P = 0Á56). Estimates of crude and adjusted HR are presented in Table IIB .
Monosomy 7 was present in 11 patients, loss of chromosome 5, 10, 11 and 13 in 6 patients each, loss of chromosome 12 in 5 patients, other chromosomes were each lost in less than 5 patients. Survival for patients with loss of chromosome 7 in MK did not differ from other patients with MK.
No significant differences in either EFS or OS between MK-R (n = 23) versus MK other (n = 18) were observed (data not shown). Years since diagnosis 
Discussion
Our study was initiated to investigate the occurrence, clinical characteristics and prognostic impact of CK and MK among children diagnosed with de novo AML. This was undertaken on a large cohort of 800 patients with eligible cytogenetic information. The size of this study exceeds other large studies on cytogenetics in children with AML, e.g. Harrison et al (2010) and von Neuhoff et al (2010) , which included 729 and 454 children, respectively. In the current cohort we found 41 (5%) patients with MK. All patients except 8 (1%) also had CK. Clinically, MK patients were younger (median age 3Á3 years) and with a female preponderance. They were morphologically associated with M7 as well as the CK/non-MK patients and there were no cases of M1. Only one MK case had FLT3-ITD and no NPM1 mutations were detected. MK patients more often received SCT in CR1 compared with other patients (P = 0Á046), which confirmed the results reported by Lee et al (2016) .
The CK-group constituted 122 (15%) patients of the total cohort, of which 89 (73%) did not have MK. CK was clinically associated with young age (median age 2Á1 years). Furthermore, there was an association with FAB M7, which could be explained by the known correlation between M7 and young age (Webb et al, 2001; Manola et al, 2013) . Consistent with previous findings in adult AML populations (Grimwade et al, 1998; Slovak et al, 2000; Byrd et al, 2002; Haferlach et al, 2012) , CK predicted an adverse prognosis in the present study and showed inferior EFS and OS compared to non-CK patients. The poor EFS associated with CK was mitigated by the omission of patients with MK and corresponds to the observations in the recent report from the AML-Berlin-Frankf€ urt-Muenster (BFM) 2004 trial (Rasche et al, 2017) . Taken together, our data suggest that, in patients with multiple non-recurrent chromosomal abnormalities, the event of chromosome loss in particular heralds an increased risk of early events, such as primary refractoriness to chemotherapy. Years since diagnosis Years since diagnosis Event-free survival The 5-year OS was higher among patients with five or more aberrations in CK compared with patients with three or four aberrations (65%; CI 50-76% vs. 55%; CI 42-66%, P = 0Á047). This is in line with previous studies showing that ≥4 aberrations did not adversely affect outcome (Harrison et al, 2010) . A possible explanation for this finding might be that high hyperdiploidy could have happened as one event in a single abnormal mitosis, which has been suggested as a mechanism in childhood ALL (Paulsson et al, 2005) , and not as a series of cumulative events albeit still included in the group of 5 or more aberrations. Hyperdiploidy is not of prognostic significance in childhood AML (Sandahl et al, 2014) .
Our study distinguishes MK as an independent predictor of inferior EFS but, in contrast to the findings by Rasche et al (2017) , the high proportion of events did not translate into a poor OS. This discrepancy may be explained by the fact that the comparison group of the current study did not include patients with CBF abnormalities who, according to previous reports, fare exceedingly well after relapse (Kaspers et al, 2013; Karlsson et al, 2017) .
It has been proposed that SCT increases OS among adults with MK (Fang et al, 2011) and this finding may also mirror the childhood setting. No patients received SCT based on adverse morphology alone (M7) or monosomy 7 or 5 in any of the NOPHO-AML protocols. The poor prognosis of refractory disease may be overcome by intensive timing of induction and early SCT (Wareham et al, 2013) . These data do not allow any conclusion on whether SCT is of benefit in those patients with MK and a favourable response to induction.
Unlike previous studies (Breems et al, 2008; Rasche et al, 2017) , we included marker and ring chromosomes as individual aberrations in both CK and MK, as it has been shown that extensive cytogenetic tests, such as spectral karyotyping, can identify marker chromosomes (Kerndrup & Kjeldsen, 2001 ). We only found marker chromosomes in 38 patients (5%), which indicates a high quality of the cytogenetic tests used.
The pathogenesis of MK is unknown. However, it is known that AML with MK shares some clinical characteristics with myelodysplastic syndrome (MDS), including low WBC count and poor response to induction chemotherapy, which suggests similar pathogenetic features with MDS rather than with AML without MK.
Our study was based on the NOPHO-AML registry, which facilitated the collection of a large group of unselected, uniformly treated patients compared to similar studies (Manola et al, 2013; Lee et al, 2016) . However, only 41 patients with MK were found and, out of these, only 8 presented MK without CK. Due to the small number of patients it was not possible to identify if the poorer prognosis was associated with the loss of specific chromosomes.
In conclusion, this study characterizes in detail the biological and clinical features of CK and MK and reports the adverse prognostic impact of these cytogenetic entities among paediatric AML patients with non-CBF abnormal karyotype. CK and MK were associated with young age and FAB M7 morphology. MK patients frequently suffered from refractory disease but the poor prognostic impact on EFS seemed to be partly overcome by the use of SCT. Most current treatment protocols employ treatment response to guide the intensity of post-induction therapy and accurate risk-stratification of CK and MK patients with an inadequate treatment response may further improve the prognosis in these patients.
